Wave Life Sciences Management
Management criteria checks 4/4
Wave Life Sciences' CEO is Paul B. Bolno, appointed in Dec 2013, has a tenure of 10.33 years. total yearly compensation is $2.67M, comprised of 23.2% salary and 76.8% bonuses, including company stock and options. directly owns 0.33% of the company’s shares, worth $2.46M. The average tenure of the management team and the board of directors is 3.6 years and 7.4 years respectively.
Key information
Paul B. Bolno
Chief executive officer
US$2.7m
Total compensation
| CEO salary percentage | 23.2% |
| CEO tenure | 10.3yrs |
| CEO ownership | 0.3% |
| Management average tenure | 3.6yrs |
| Board average tenure | 7.4yrs |
Recent management updates
Recent updates
We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth
Apr 09
Wave Life Sciences' Weighty Ambition: Carving Out Obesity Niche
Mar 09Wave Life Sciences Ltd.'s (NASDAQ:WVE) 30% Price Boost Is Out Of Tune With Revenues
Mar 03We're Interested To See How Wave Life Sciences (NASDAQ:WVE) Uses Its Cash Hoard To Grow
Sep 13Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Cut Their EPS Forecasts Substantially
May 08Here's Why Wave Life Sciences (NASDAQ:WVE) Must Use Its Cash Wisely
Mar 30Are Investors Undervaluing Wave Life Sciences Ltd. (NASDAQ:WVE) By 47%?
Jan 20Some Analysts Just Cut Their Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates
Nov 11Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?
Aug 12Wave Life Sciences Q2 2022 Earnings Preview
Aug 10Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?
Apr 21Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Invest In Growth?
Jan 11We Think Wave Life Sciences (NASDAQ:WVE) Needs To Drive Business Growth Carefully
Sep 24What Does The Future Hold For Wave Life Sciences Ltd. (NASDAQ:WVE)? These Analysts Have Been Cutting Their Estimates
Aug 07Wave Life Sciences posts proof-of-concept data from genetic disorder study
Jun 02Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Slashed This Year's Estimates
May 15Things Look Grim For Wave Life Sciences Ltd. (NASDAQ:WVE) After Today's Downgrade
Apr 02Wave Life Sciences (NASDAQ:WVE) Share Prices Have Dropped 80% In The Last Three Years
Feb 19Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?
Jan 13
Here's What We Think About Wave Life Sciences' (NASDAQ:WVE) CEO Pay
Dec 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$58m |
| Sep 30 2023 | n/a | n/a | -US$85m |
| Jun 30 2023 | n/a | n/a | -US$131m |
| Mar 31 2023 | n/a | n/a | -US$151m |
| Dec 31 2022 | US$3m | US$618k | -US$162m |
| Sep 30 2022 | n/a | n/a | -US$153m |
| Jun 30 2022 | n/a | n/a | -US$120m |
| Mar 31 2022 | n/a | n/a | -US$118m |
| Dec 31 2021 | US$4m | US$597k | -US$122m |
| Sep 30 2021 | n/a | n/a | -US$116m |
| Jun 30 2021 | n/a | n/a | -US$143m |
| Mar 31 2021 | n/a | n/a | -US$145m |
| Dec 31 2020 | US$1m | US$579k | -US$150m |
| Sep 30 2020 | n/a | n/a | -US$178m |
| Jun 30 2020 | n/a | n/a | -US$196m |
| Mar 31 2020 | n/a | n/a | -US$197m |
| Dec 31 2019 | US$4m | US$579k | -US$194m |
| Sep 30 2019 | n/a | n/a | -US$175m |
| Jun 30 2019 | n/a | n/a | -US$162m |
| Mar 31 2019 | n/a | n/a | -US$156m |
| Dec 31 2018 | US$6m | US$541k | -US$147m |
| Sep 30 2018 | n/a | n/a | -US$140m |
| Jun 30 2018 | n/a | n/a | -US$127m |
| Mar 31 2018 | n/a | n/a | -US$116m |
| Dec 31 2017 | US$3m | US$515k | -US$102m |
Compensation vs Market: Paul B.'s total compensation ($USD2.67M) is about average for companies of similar size in the US market ($USD3.30M).
Compensation vs Earnings: Paul B.'s compensation has been consistent with company performance over the past year.
CEO
Paul B. Bolno (49 yo)
10.3yrs
Tenure
US$2,667,997
Compensation
Dr. Paul B. Bolno, M.D., MBA serves as an Independent Director at SQZ Biotechnologies Company since June 2020. Since May 2020 he has served as Chairman of the Scientific Advisory Group for the Nucleic Acid...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10.3yrs | US$2.67m | 0.33% $ 2.5m | |
| CFO & Principal Accounting Officer | 3.3yrs | US$1.15m | 0.028% $ 204.9k | |
| Chief Technology Officer | 3.9yrs | US$1.23m | 0.079% $ 581.9k | |
| Head of Investor Relations | 5yrs | no data | no data | |
| Senior VP & General Counsel | 7.9yrs | no data | no data | |
| Senior VP of Corporate Development & Head of Emerging Areas | 7.3yrs | US$1.68m | 0.065% $ 481.5k | |
| Senior VP & Head of Human Resources | 1.3yrs | no data | no data | |
| Senior Vice President of Chemistry | 2.4yrs | no data | no data | |
| Chief Development Officer | 1.5yrs | no data | no data | |
| Senior Vice President of Translational Medicine | 1.3yrs | no data | no data |
3.6yrs
Average Tenure
50.5yo
Average Age
Experienced Management: WVE's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10yrs | US$2.67m | 0.33% $ 2.5m | |
| Director | 10.8yrs | US$628.06k | 0.025% $ 181.2k | |
| Independent Director | 4.6yrs | US$116.65k | 0.059% $ 436.0k | |
| Independent Chairperson | 7.4yrs | US$144.15k | 0.072% $ 530.0k | |
| Independent Director | 7.2yrs | US$110.65k | 0.072% $ 530.0k | |
| Independent Director | 9.3yrs | US$92.65k | no data | |
| Independent Director | 11.8yrs | US$92.65k | 0% $ 0 | |
| Independent Director | 4.6yrs | US$107.65k | 0.059% $ 436.0k | |
| Independent Director | 3.7yrs | US$94.15k | 0.047% $ 344.0k |
7.4yrs
Average Tenure
55yo
Average Age
Experienced Board: WVE's board of directors are considered experienced (7.4 years average tenure).